About Precigen, Inc.
https://www.precigen.comPrecigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies.
CEO
Helen Sabzevari MPH,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 106
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Cantor Fitzgerald
Overweight
JP Morgan
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
THIRD SECURITY, LLC
Shares:83.47M
Value:$368.08M
PATIENT CAPITAL MANAGEMENT, LLC
Shares:26.46M
Value:$116.69M
TANG CAPITAL MANAGEMENT LLC
Shares:12.4M
Value:$54.68M
Summary
Showing Top 3 of 187
About Precigen, Inc.
https://www.precigen.comPrecigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.92M ▲ | $36.37M ▲ | $-146.34M ▼ | -5.01K% ▼ | $-1.1 ▼ | $-144.64M ▼ |
| Q2-2025 | $856K ▼ | $31.07M ▲ | $-26.64M ▲ | -3.11K% ▲ | $-0.09 ▲ | $-27.23M ▲ |
| Q1-2025 | $1.34M ▲ | $22.84M ▼ | $-54.15M ▼ | -4.04K% ▼ | $-0.18 ▼ | $-53.52M ▼ |
| Q4-2024 | $1.19M ▲ | $28.54M ▲ | $-19.73M ▲ | -1.66K% ▲ | $-0.07 ▲ | $-19.15M ▲ |
| Q3-2024 | $953K | $21.21M | $-23.98M | -2.52K% | $-0.09 | $-23.29M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $121.14M ▲ | $171.26M ▲ | $129.4M ▼ | $41.87M ▲ |
| Q2-2025 | $59.75M ▼ | $101.9M ▼ | $138.68M ▼ | $-36.78M ▼ |
| Q1-2025 | $80.24M ▼ | $128.79M ▼ | $142.85M ▲ | $-14.06M ▼ |
| Q4-2024 | $97.91M ▲ | $145.27M ▲ | $106.75M ▲ | $38.51M ▼ |
| Q3-2024 | $28.63M | $83.47M | $28.1M | $55.38M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-146.34M ▼ | $-29.07M ▼ | $-63.39M ▼ | $93.01M ▲ | $562K ▼ | $-29.46M ▼ |
| Q2-2025 | $-26.64M ▲ | $-18.98M ▼ | $28.44M ▲ | $-1.77M ▼ | $7.7M ▲ | $-19.94M ▼ |
| Q1-2025 | $-54.15M ▼ | $-16.32M ▼ | $-6.46M ▲ | $-679K ▼ | $-23.46M ▼ | $-16.95M ▼ |
| Q4-2024 | $-19.73M ▲ | $-8.24M ▲ | $-65.37M ▼ | $78.4M ▲ | $4.79M ▼ | $-9.27M ▲ |
| Q3-2024 | $-23.98M | $-22.73M | $5.65M | $32.13M | $15.12M | $-23.61M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Biopharmaceuticals Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Exemplar Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Operating Segments | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2022 | Q1-2022 | Q2-2022 | Q3-2022 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Helen Sabzevari MPH,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 106
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Cantor Fitzgerald
Overweight
JP Morgan
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
THIRD SECURITY, LLC
Shares:83.47M
Value:$368.08M
PATIENT CAPITAL MANAGEMENT, LLC
Shares:26.46M
Value:$116.69M
TANG CAPITAL MANAGEMENT LLC
Shares:12.4M
Value:$54.68M
Summary
Showing Top 3 of 187